4551 — Torii Pharmaceutical Co Share Price
Last trade - 00:00- ¥122bn
- ¥79bn
- ¥60bn
- 79
- 44
- 93
- 85
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 2.73% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.03 | ||
| Price to Tang. Book | 1.03 | ||
| Price to Free Cashflow | 36.04 | ||
| Price to Sales | 2.06 | ||
| EV to EBITDA | 11.68 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.39% | ||
| Return on Equity | 4.17% | ||
| Operating Margin | 10.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 41,700 | 46,987 | 48,896 | 54,638 | 60,426 | 61,200 | n/a | 7.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +234.67 | -17.29 | +15.94 | +5.07 | +25.19 | +32.59 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
Directors
- Goichi Matsuda PRE (53)
- Yukihiro Takashima FID
- Katsunobu Fujiwara MEO (57)
- Atsuyuki Kakee MEO (57)
- Nobumasa Kondo MEO
- Noriaki Nishino EXO
- Masaki Sunami EXO (63)
- Toshio Fukuoka IND (67)
- Masao Torikai IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 1st, 1921
- Public Since
- October 1st, 2013
- No. of Shareholders
- 4,434
- No. of Employees
- 592
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 28,111,232
- Address
- Torii Nihombashi Bldg., CHUO-KU, 103-8439
- Web
- https://www.torii.co.jp/
- Phone
- +81 332316811
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 4551
Upcoming Events for 4551
Dividend For 4551.T - 60.0000 JPY
Q2 2025 Torii Pharmaceutical Co Ltd Earnings Release
Similar to 4551
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 23:45 UTC, shares in Torii Pharmaceutical Co are trading at ¥4,435. This share price information is delayed by 15 minutes.
Shares in Torii Pharmaceutical Co last closed at ¥4,435 and the price had moved by +17.02% over the past 365 days. In terms of relative price strength the Torii Pharmaceutical Co share price has outperformed the Nikkei 225 Index by +23.32% over the past year.
The overall consensus recommendation for Torii Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Torii Pharmaceutical Co dividend yield is 2.71% based on the trailing twelve month period.
Last year, Torii Pharmaceutical Co paid a total dividend of ¥120, and it currently has a trailing dividend yield of 2.71%.Looking ahead, shares in Torii Pharmaceutical Co are due to go ex-dividend on 2025-06-27 and the next dividend pay date is 2025-09-01.
Torii Pharmaceutical Co are due to go ex-dividend on 2025-06-27 and the next dividend pay date is 2025-09-01. The historic dividend yield on Torii Pharmaceutical Co shares is currently 2.71%.
To buy shares in Torii Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥4,435, shares in Torii Pharmaceutical Co had a market capitalisation of ¥122bn.
Here are the trading details for Torii Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4551
Based on an overall assessment of its quality, value and momentum Torii Pharmaceutical Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Torii Pharmaceutical Co is ¥4,583. That is 3.34% above the last closing price of ¥4,435.
Analysts covering Torii Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥245 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Torii Pharmaceutical Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +23.91%.
As of the last closing price of ¥4,435, shares in Torii Pharmaceutical Co were trading +5.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Torii Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥4,435.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Torii Pharmaceutical Co's management team is headed by:
- Goichi Matsuda - PRE
- Yukihiro Takashima - FID
- Katsunobu Fujiwara - MEO
- Atsuyuki Kakee - MEO
- Nobumasa Kondo - MEO
- Noriaki Nishino - EXO
- Masaki Sunami - EXO
- Toshio Fukuoka - IND
- Masao Torikai - IND